Use of anti-HER2 antibody-drug conjugate in the treatment ofurothelial carcinoma

The present invention relates to the use of an anti-HER2 antibody-drug conjugate (ADC) in the preparation of a medicament for the treatment of urothelial carcinoma. The medicament of the present invention is safe and effective for patients with urothelial carcinoma, especially locally advanced or me...

Full description

Saved in:
Bibliographic Details
Main Author FANG, JIAN-MIN
Format Patent
LanguageChinese
English
Published 01.02.2025
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the use of an anti-HER2 antibody-drug conjugate (ADC) in the preparation of a medicament for the treatment of urothelial carcinoma. The medicament of the present invention is safe and effective for patients with urothelial carcinoma, especially locally advanced or metastatic urothelial carcinoma, and can effectively prolong the survival of the patient.
Bibliography:Application Number: TW20240114808